^
Association details:
| Biomarker: | HR positive + HER-2 negative |
|---|---|
| Cancer: | Male Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
Published date:
10/20/2021
Excerpt:
This report examined the benefits and risks of palbociclib plus endocrine therapy (ET) in men with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)….From medical and pharmacy records, 1139 men with MBC were identified; in the first-line setting, median duration of treatment was longer with palbociclib plus ET (n=37; 8.5 months; 95% CI; 4.4-13.0) than ET alone (n=214; 4.3 months; 95% CI; 3.0-5.7) and specifically, was longer with palbociclib plus letrozole (n=26; 9.4 months; 95% CI; 4.4-14.0) than letrozole alone (n=63; 3.0 months; 95% CI; 1.8-4.8).
Secondary therapy:
letrozole
DOI:
10.1002/cpt.2454
